Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov-Dec;64(6):541-6.
doi: 10.1016/j.ihj.2012.07.005. Epub 2012 Jul 27.

In vivo assessment of stent recoil of biodegradable polymer-coated cobalt-chromium sirolimus-eluting coronary stent system

Atul D Abhyankar  1 , Ashok S Thakkar
Affiliations

In vivo assessment of stent recoil of biodegradable polymer-coated cobalt-chromium sirolimus-eluting coronary stent system

Atul D Abhyankar et al. Indian Heart J. 2012 Nov-Dec.

Abstract

Introduction: Immediate and acute stent recoil has been observed following balloon deflation in normal and diseased coronary arteries, and the degree varies by stent design.

Methods: A total of 19 patients, who underwent elective stent implantation for single de novo native coronary artery lesions, were enrolled: all patients treated with the biodegradable polymer-coated sirolimus-eluting cobalt-chromium coronary stent system (Supralimus-Core(®)). The immediate, acute and cumulative stent recoil was assessed by quantitative coronary angiography. The cumulative stent recoil was measured at 24 h of stent implantation.

Results: The absolute late loss due to recoil was found 0.08 ± 0.19 mm for Immediate Stent Recoil (ISR), 0.05 ± 0.21 mm for Acute Stent Recoil (ASR) and 0.11 ± 0.25 mm for Cumulative Stent Recoil (CSR) respectively.

Conclusions: In vivo acute stent recoil of the Supralimus-Core(®) has higher radial strength compared to other available standard drug-eluting stents.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Immediate, acute and cumulative stent recoil.
Fig. 2
Fig. 2
Sequential measurements of minimal luminal diameter of pre-PCI, stent expansion, post-stent expansion and follow-up (each line represents the data from a single patient).
Fig. 3
Fig. 3
Normality distribution of mean acute recoil.
Fig. 4
Fig. 4
Lesion length vs. immediate recoil.
Fig. 5
Fig. 5
Reference vessel diameter vs. immediate recoil.
Fig. 6
Fig. 6
Recoil box plot in diabetic and non-diabetic patients.
Fig. 7
Fig. 7
Recoil comparisons across current stent platforms.
See this image and copyright information in PMC

References

    1. Tanimoto S., Serruys P.W., Thuesen L. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70(4):515–523. - PubMed
    1. Painter J.A., Mintz G.S., Wong S.C. Serial intravascular ultrasound studies fail to show evidence of chronic Palmaz–Schatz stent recoil. Am J Cardiol. 1995;75(5):398–400. - PubMed
    1. Post M.J., Borst C., Kuntz R.E. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation. 1994;89(6):2816–2821. - PubMed
    1. Isner J.M. Vascular remodeling. Honey, I think I shrunk the artery. Circulation. 1994;89(6):2937–2941. - PubMed
    1. Regar E., Schaar J., Serruys P.W. Images in cardiology. Acute recoil in sirolimus eluting stent: real time, in vivo assessment with optical coherence tomography. Heart. 2006;92(1):123. - PMC - PubMed

Publication types